The FDA has asked for more safety information on the drug Pargluva, which Bristol-Myers Squibb and Merck plan to market for treatment of diabetes. An FDA advisory panel last month recommended approval of the drug despite concerns about possible heart problems, but the agency told the companies it wants information from clinical trials "to address more fully the cardiovascular safety profile," the companies said.

Related Summaries